Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Cash from Financing Activities of -$4000.0 for Q4 2025, down 101.67% sequentially from $240000.0 in Q1 2025, and down 109.76% YoY from $41000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Cash from Financing Activities for 6 years, with the latest figure at -$4000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 109.76% year-over-year to -$4000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $236000.0 (down 26.48% YoY) and the FY2025 annual result came in at $236000.0, down 26.48% from the prior year.
- Cash from Financing Activities retreated to -$4000.0 in Q4 2025 per RAPH's latest filing, from $240000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $820000.0 in Q4 2021 and troughed at -$4000.0 in Q4 2025.
- A 5-year average of $239705.9 and a median of $149000.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 1390.0% in 2023, then tumbled 109.76% in 2025.
- Over 5 years, Cash from Financing Activities stood at $820000.0 in 2021, then tumbled by 42.44% to $472000.0 in 2022, then plunged by 95.97% to $19000.0 in 2023, then jumped by 115.79% to $41000.0 in 2024, then sank by 109.76% to -$4000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$4000.0, $240000.0, and $41000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Sep 30, 2023 | 689,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Dec 31, 2022 | 472,000.00 |
| Dec 31, 2022 | 472,000.00 |